VSA003 not checked
Visirna Therapeutics HK Limited · AROANG3
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “Significant reduction in ANGPLT3 levels is expected to reduce plasma LDL-C and TG levels and may lead to the reduction of risk of coronary heart disease and cardiovascular events associated with hypertriglyceridemia and LDL-C in subjects with persistent dyslipidemia. In this clinical study, the efficacy and safety of VSA003, an RNAi-based therapeutic targeting ANGPTL3, will be evaluated in subjects with HoFH.”In the company’s words, NCT06712771 on ClinicalTrials.gov
- Other names
- AROANG3 · Zodasiran
Other drugs for Homozygous Familial Hypercholesterolemia (HoFH)
- ZodasiranArrowhead · Phase 3
- InclisiranNovartis Pharmaceuticals · Phase 3
- EDP167Eddingpharm (Zhuhai) Co., Ltd. · Phase 2
- SHR-1918Hengrui · Phase 2
- CTX310CRISPR Therapeutics AG · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Dec 2025 | A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients | |
| Phase 1Completed | 7 May 2024 | A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026